PMID- 30214893
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 2230-5254 (Electronic)
IS  - 2230-5254 (Linking)
VI  - 7
DP  - 2018
TI  - Role of a clinical pharmacist as part of a multidisciplinary care team in the 
      treatment of HCV in patients living with HIV/HCV coinfection.
PG  - 105-111
LID - 10.2147/IPRP.S169282 [doi]
AB  - BACKGROUND: The objective of the study was to evaluate the role of a clinical 
      pharmacist in hepatitis C virus (HCV) treatment of patients living with HIV/HCV 
      coinfection. METHODS: We conducted a descriptive study to quantify the functions 
      of a clinical pharmacist in HCV treatment of patients living with HIV/HCV 
      coinfection who were initiating HCV treatment at a publicly funded clinic between 
      March 18, 2015 and September 15, 2016. The clinical pharmacist's role was 
      categorized into eight categories: 1) HCV prior authorization (PA) completion; 2) 
      HCV medication adherence counseling; 3) HCV drug-drug interaction (DDI) 
      counseling and screening; 4) HCV medication counseling regarding common adverse 
      events (AEs); 5) HCV counseling regarding HCV treatment outcomes and risk of 
      reinfection; 6) ordering laboratory tests and interpretation of HCV laboratory 
      values; 7) HIV medication AE assessment; and 8) other (including refilling 
      medications and management of other comorbidities). RESULTS: One hundred and 
      thirty-five patients initiated treatment during this timeframe: 77.0% were males, 
      56.3% non-cirrhotic, 77.0% HCV treatment-naive, 45.9% HCV genotype 1a, and 83.0% 
      initiated on ledipasvir/sofosbuvir. The clinical pharmacist completed 150 PAs, 
      counseled on HCV medication adherence in 79.2% of patients, conducted HCV DDI 
      counseling and screening in 54.2%, and monitored HCV medication AEs in 54.2%. The 
      clinical pharmacist counseled patients on HCV treatment outcomes and risk of 
      reinfection in 53.1%, ordered laboratory tests in 44.8%, and reported and 
      interpreted laboratory values in 44.8%. The clinical pharmacist assessed HIV 
      medication AEs in 54.2% of patients and participated in other activities in 
      42.7%. CONCLUSION: A clinical pharmacist's expertise as part of a 
      multidisciplinary care team facilitates optimal treatment outcomes and provides 
      critical support in the management of DAA therapy in individuals living with 
      HIV/HCV coinfection.
FAU - Olea, Antonio Jr
AU  - Olea A Jr
AD  - Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San 
      Francisco General, San Francisco, CA, USA, antonio.olea.pharmd@gmail.com.
FAU - Grochowski, Janet
AU  - Grochowski J
AD  - Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San 
      Francisco General, San Francisco, CA, USA, antonio.olea.pharmd@gmail.com.
FAU - Luetkemeyer, Anne F
AU  - Luetkemeyer AF
AD  - Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San 
      Francisco General, San Francisco, CA, USA, antonio.olea.pharmd@gmail.com.
FAU - Robb, Valerie
AU  - Robb V
AD  - Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San 
      Francisco General, San Francisco, CA, USA, antonio.olea.pharmd@gmail.com.
FAU - Saberi, Parya
AU  - Saberi P
AD  - Department of Medicine, School of Medicine, University of California, San 
      Francisco, San Francisco, CA, USA.
LA  - eng
GR  - K23 MH097649/MH/NIMH NIH HHS/United States
PT  - Journal Article
DEP - 20180828
PL  - New Zealand
TA  - Integr Pharm Res Pract
JT  - Integrated pharmacy research & practice
JID - 101656778
PMC - PMC6118274
OTO - NOTNLM
OT  - HIV/HCV
OT  - clinical pharmacist
OT  - coinfection
OT  - direct acting-antivirals
OT  - multidisciplinary care team
COIS- Disclosure Parya Saberi has received a National Institute of Mental Health Grant 
      (K23MH097649). Anne F Luetkemeyer has received research grant support to the 
      University of California, San Francisco from AbbVie, Gilead, and Merck. The 
      authors report no other conflicts of interest in this work.
EDAT- 2018/09/15 06:00
MHDA- 2018/09/15 06:01
PMCR- 2018/08/28
CRDT- 2018/09/15 06:00
PHST- 2018/09/15 06:00 [entrez]
PHST- 2018/09/15 06:00 [pubmed]
PHST- 2018/09/15 06:01 [medline]
PHST- 2018/08/28 00:00 [pmc-release]
AID - iprp-7-105 [pii]
AID - 10.2147/IPRP.S169282 [doi]
PST - epublish
SO  - Integr Pharm Res Pract. 2018 Aug 28;7:105-111. doi: 10.2147/IPRP.S169282. 
      eCollection 2018.